(Circulation. 1997;96:636-645.)
© 1997 American Heart Association, Inc.
Articles |
Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery
From the Departments of Cardiology and Surgery (G.K.), University of Tübingen, Germany.
Correspondence to Dorothea I. Axel, PhD, Dept of Cardiology, University of Tübingen, Otfried-Müller St 10, D-72076 Tübingen, Germany. E-mail dorothea.axel{at}uni-tuebingen.de
Background The antineoplastic compound paclitaxel (Taxol) causes an increased assembly of extraordinarily stable microtubules. The present study was designed to characterize the effects of paclitaxel on proliferation and migration of human arterial smooth muscle cells (haSMCs) in vitro and on neointima formation in an in vivo experimental rabbit model.
Methods and Results Both monocultures of haSMCs and cocultures with human arterial endothelial cells (haECs) were used. Cell growth after 4, 8, and 14 days was determined in the absence or presence of platelet-derived growth factor-AB (PDGF-AB), basic fibroblast growth factor (bFGF), or thrombin. Nonstop paclitaxel exposure, as well as single-dose applications of paclitaxel for 24 hours or even 20 minutes (0.1 to 10.0 µmol/L), caused a complete and prolonged inhibition of haSMC growth up to day 14, with an IC50 of 2.0 nmol/L. Mitogens or cocultures with stimulating haECs did not significantly attenuate paclitaxel-induced effects. Immunohistochemistry showed characteristic cytoskeletal changes predominantly in the microtubule network. Additionally, in 20 male New Zealand White rabbits, intimal plaques were produced by electrical stimulation. In 10 animals, paclitaxel was locally applied by use of microporous balloons. Histologically, the intima wall area, wall thickness, and degree of stenosis were reduced significantly in paclitaxel-treated animals compared with controls.
Conclusions Our data show that paclitaxel inhibits haSMC proliferation and migration in a dose-dependent manner in monocultures and cocultures even in the presence of mitogens. Furthermore, paclitaxel prevents neointima formation in rabbits after balloon angioplasty. The long-lasting effect after just several minutes' exposure time makes this lipophilic substance a promising candidate for local antiproliferative therapy of restenosis.
Key Words: restenosis • paclitaxel • pharmacology • muscle, smooth • endothelium
This article has been cited by other articles:
 |
|
 |
|
  M. Unverdorben, C. Vallbracht, B. Cremers, H. Heuer, C. Hengstenberg, C. Maikowski, G. S. Werner, D. Antoni, F. X. Kleber, W. Bocksch, et al. Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis Circulation, June 16, 2009; 119(23): 2986 - 2994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mahmud, J. A. Ormiston, M. A. Turco, J. J. Popma, N. J. Weissman, C. D. O'Shaughnessy, T. Mann, J. J. Hall, T. F. McGarry, L. A. Cannon, et al. TAXUS Liberte Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus: Results From the TAXUS ATLAS Program J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 240 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Pendyala, J. Li, T. Shinke, S. Geva, X. Yin, J. P. Chen, S. B. King III, K. A. Robinson, N. A.F. Chronos, and D. Hou Endothelium-Dependent Vasomotor Dysfunction in Pig Coronary Arteries With Paclitaxel-Eluting Stents Is Associated With Inflammation and Oxidative Stress J. Am. Coll. Cardiol. Intv., March 1, 2009; 2(3): 253 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chiu, D. T. Ko, P. C. Austin, E. A. Cohen, J. L. Velianou, R. Goeree, G. Blackhouse, and J. V. Tu Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 96 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Ostovan, R. Mollazadeh, J. Kojuri, and M. Mirabadi Experience with Paclitaxel-Eluting Infinnium Coronary Stents Asian Cardiovasc Thorac Ann, December 1, 2008; 16(6): 454 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hamilos, J. Sarma, M. Ostojic, T. Cuisset, G. Sarno, N. Melikian, A. Ntalianis, O. Muller, E. Barbato, B. Beleslin, et al. Interference of Drug-Eluting Stents With Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses Circ Cardiovasc Intervent, December 1, 2008; 1(3): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Choung, S.-E. Jin, M. J. Lee, C.-K. Kim, and J.-M. Hwang Slow-Releasing Paclitaxel in Polytetrafluoroethylene/Polylactide-co-glycolide Laminate Delays Adjustment after Strabismus Surgery in Rabbit Model Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5340 - 5345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Werk, S. Langner, B. Reinkensmeier, H.-F. Boettcher, G. Tepe, U. Dietz, N. Hosten, B. Hamm, U. Speck, and J. Ricke Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial Circulation, September 23, 2008; 118(13): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cyrus, H. Zhang, J. S. Allen, T. A. Williams, G. Hu, S. D. Caruthers, S. A. Wickline, and G. M. Lanza Intramural Delivery of Rapamycin With {alpha}v{beta}3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 820 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schachner, C. Steger, S. Heiss, N. Bonaros, W. Sterlacci, G. Laufer, and J. Bonatti Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S W Park, S H Lee, C H Kim, G S Jeon, S J Hong, J G Yi, and H J Jeon Inhibition of pseudointimal hyperplasia in swine TIPS models: the efficacy of local delivery of paclitaxel using a perforated balloon catheter Br. J. Radiol., September 1, 2007; 80(957): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Finn, G. Nakazawa, M. Joner, F. D. Kolodgie, E. K. Mont, H. K. Gold, and R. Virmani Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1500 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Scheller, U. Speck, and M. Bohm Prevention of restenosis: is angioplasty the answer? Heart, May 1, 2007; 93(5): 539 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Murphy, T. W. Johnson, M. H. Chamberlain, S. I. Rizvi, M. Wyatt, S. J. George, G. D. Angelini, K. R. Karsch, M. Oberhoff, and A. C. Newby Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts Cardiovasc Res, February 1, 2007; 73(3): 607 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Scheller, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, M. Bohm, and U. Speck Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., November 16, 2006; 355(20): 2113 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Lee, H. Y. Nam, T. Kwon, S. J. Kim, G. Y. Kwon, H. J. Jeon, H. J. Lim, W. K. Lee, J.-s. Park, J. Y. Ko, et al. Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2432 - 2438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Cho, T.-Y. Kim, H.-J. Cho, K.-W. Park, S.-Y. Zhang, J.-H. Kim, S.-H. Kim, J.-Y. Hahn, H.-J. Kang, Y.-B. Park, et al. The Effect of Stem Cell Mobilization by Granulocyte-Colony Stimulating Factor on Neointimal Hyperplasia and Endothelial Healing After Vascular Injury With Bare-Metal Versus Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., July 18, 2006; 48(2): 366 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patterson, S. Mapera, H.-H. Li, N. Madamanchi, E. Hilliard, R. Lineberger, R. Herrmann, and P. Charles Comparative Effects of Paclitaxel and Rapamycin on Smooth Muscle Migration and Survival: Role of Akt-Dependent Signaling Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1473 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different J. Am. Coll. Cardiol., February 21, 2006; 47(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Alvarez Jr and N. K. Kapur Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis Journal of Pharmacy Practice, December 1, 2005; 18(6): 461 - 478. [Abstract] [PDF]
|
|
|
|
|
|
J.W. Fischer Dexamethasone: Effects on neointimal hyperplasia and vessel integrity Cardiovasc Res, December 1, 2005; 68(3): 350 - 352. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Nawarskas and L. A. Osborn Paclitaxel-eluting stents in coronary artery disease Am. J. Health Syst. Pharm., November 1, 2005; 62(21): 2241 - 2251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Granada, D. Ensenat, A. N. Keswani, G. L. Kaluza, A. E. Raizner, X.-m. Liu, K. J. Peyton, M. A. Azam, H. Wang, and W. Durante Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A H Gershlick Drug eluting stents in 2005 Heart, June 1, 2005; 91(suppl_3): iii24 - iii31. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Moses, R. Mehran, E. Nikolsky, J. M. Lasala, W. Corey, G. Albin, C. Hirsch, M. B. Leon, M. E. Russell, S. G. Ellis, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: Analysis from the TAXUS-IV trial J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1165 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Hermiller, A. Raizner, L. Cannon, P. A. Gurbel, M. A. Kutcher, S. C. Wong, M. E. Russell, S. G. Ellis, R. Mehran, G. W. Stone, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1172 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lansky, R. A. Costa, M. Mooney, M. G. Midei, H. K. Lui, W. Strickland, R. Mehran, M. B. Leon, M. E. Russell, S. G. Ellis, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1180 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Prasad, K. R. Resmi, L. K. Krishnan, and R. Vaishnav Survival of Endothelial Cells in vitro on Paclitaxel-loaded Coronary Stents J Biomater Appl, April 1, 2005; 19(4): 271 - 286. [Abstract] [PDF]
|
|
|
|
|
|
K. Peppel, L. Zhang, E. S. Orman, P.-O. Hagen, A. Amalfitano, L. Brian, and N. J. Freedman Activation of vascular smooth muscle cells by TNF and PDGF: overlapping and complementary signal transduction mechanisms Cardiovasc Res, February 15, 2005; 65(3): 674 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, C. Abramjuk, U. Bernhardt, M. Bohm, and G. Nickenig Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis Circulation, August 17, 2004; 110(7): 810 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R Sindermann, V. Verin, J. W Hopewell, H. P. Rodemann, and J. H Hendry Biological aspects of radiation and drug-eluting stents for the prevention of restenosis Cardiovasc Res, July 1, 2004; 63(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lansky, R. A. Costa, G. S. Mintz, Y. Tsuchiya, M. Midei, D. A. Cox, C. O'Shaughnessy, R. A. Applegate, L. A. Cannon, M. Mooney, et al. Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial Circulation, April 27, 2004; 109(16): 1948 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-L. Zheng, Y. Gui, G. Du, M. A. Frohman, and D.-Q. Peng Calphostin-C Induction of Vascular Smooth Muscle Cell Apoptosis Proceeds through Phospholipase D and Microtubule Inhibition J. Biol. Chem., February 20, 2004; 279(8): 7112 - 7118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gershlick, I. De Scheerder, B. Chevalier, A. Stephens-Lloyd, E. Camenzind, C. Vrints, N. Reifart, L. Missault, J.-J. Goy, J. A. Brinker, et al. Inhibition of Restenosis With a Paclitaxel-Eluting, Polymer-Free Coronary Stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) Trial Circulation, February 3, 2004; 109(4): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanabe, P. W. Serruys, M. Degertekin, G. Guagliumi, E. Grube, C. Chan, T. Munzel, J. Belardi, W. Ruzyllo, L. Bilodeau, et al. Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II Trial Circulation, January 20, 2004; 109(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg, et al. A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease N. Engl. J. Med., January 15, 2004; 350(3): 221 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, B. Romeike, A. Schmitt, M. Sovak, M. Bohm, and H.-P. Stoll Contrast media as carriers for local drug delivery: Successful inhibition of neointimal proliferation in the porcine coronary stent model Eur. Heart J., August 1, 2003; 24(15): 1462 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Park, W. H. Shim, D. S. Ho, A. E. Raizner, S.-W. Park, M.-K. Hong, C. W. Lee, D. Choi, Y. Jang, R. Lam, et al. A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis N. Engl. J. Med., April 17, 2003; 348(16): 1537 - 1545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-K. Hong, G. S. Mintz, C. W. Lee, J.-M. Song, K.-H. Han, D.-H. Kang, J.-K. Song, J.-J. Kim, N. J. Weissman, N. E. Fearnot, et al. Paclitaxel Coating Reduces In-Stent Intimal Hyperplasia in Human Coronary Arteries: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT) Circulation, February 4, 2003; 107(4): 517 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanabe, P. W. Serruys, E. Grube, P. C. Smits, G. Selbach, W. J. van der Giessen, M. Staberock, P. de Feyter, R. Muller, E. Regar, et al. TAXUS III Trial: In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation Circulation, February 4, 2003; 107(4): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Grube, S. Silber, K. E. Hauptmann, R. Mueller, L. Buellesfeld, U. Gerckens, and M. E. Russell TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions Circulation, January 7, 2003; 107(1): 38 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Lanza, X. Yu, P. M. Winter, D. R. Abendschein, K. K. Karukstis, M. J. Scott, L. K. Chinen, R. W. Fuhrhop, D. E. Scherrer, and S. A. Wickline Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis Circulation, November 26, 2002; 106(22): 2842 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Ingber Mechanical Signaling and the Cellular Response to Extracellular Matrix in Angiogenesis and Cardiovascular Physiology Circ. Res., November 15, 2002; 91(10): 877 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kataoka, E. Grube, Y. Honda, Y. Morino, S.-H. Hur, H. N. Bonneau, A. Colombo, C. Di Mario, G. Guagliumi, K. E. Hauptmann, et al. 7-Hexanoyltaxol-Eluting Stent for Prevention of Neointimal Growth: An Intravascular Ultrasound Analysis From the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE) Circulation, October 1, 2002; 106(14): 1788 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yasuda, T. Noguchi, M. Gohda, T. Arai, N. Tsutsui, Y. Nakayama, T. Matsuda, and H. Nonogi Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model Cardiovasc Res, February 1, 2002; 53(2): 481 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jorgensen, H. Kelbaek, S. Helqvist, G. V. H. Jensen, K. Saunamaki, J. Kastrup, O. Havndrup, H. Bundgaard, J. Kyst Madsen, M. Christiansen, et al. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1434 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Regar, G Sianos, and P W Serruys Stent development and local drug delivery Br. Med. Bull., October 1, 2001; 59(1): 227 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Work, A. R. McPhaden, N. J. Pyne, S. Pyne, R. M. Wadsworth, and C. L. Wainwright Short-Term Local Delivery of an Inhibitor of Ras Farnesyltransferase Prevents Neointima Formation In Vivo After Porcine Coronary Balloon Angioplasty Circulation, September 25, 2001; 104(13): 1538 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Liistro and A Colombo Late acute thrombosis after paclitaxel eluting stent implantation Heart, September 1, 2001; 86(3): 262 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Honda, E. Grube, L. M. de la Fuente, P. G. Yock, S. H. Stertzer, and P. J. Fitzgerald Novel Drug-Delivery Stent: Intravascular Ultrasound Observations From the First Human Experience With the QP2-Eluting Polymer Stent System Circulation, July 24, 2001; 104(4): 380 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Farb, P. F. Heller, S. Shroff, L. Cheng, F. D. Kolodgie, A. J. Carter, D. S. Scott, J. Froehlich, and R. Virmani Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent Circulation, July 24, 2001; 104(4): 473 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boehm and E. G. Nabel Cell Cycle and Cell Migration : New Pieces to the Puzzle Circulation, June 19, 2001; 103(24): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
|
|
A. W. Heldman, L. Cheng, G. M. Jenkins, P. F. Heller, D.-W. Kim, M. Ware Jr, C. Nater, R. H. Hruban, B. Rezai, B. S. Abella, et al. Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis Circulation, May 8, 2001; 103(18): 2289 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I Axel, A. Frigge, J. Dittmann, H. Runge, I. Spyridopoulos, R. Riessen, R. Viebahn, and K. R Karsch All-trans retinoic acid regulates proliferation, migration, differentiation, and extracellular matrix turnover of human arterial smooth muscle cells Cardiovasc Res, March 1, 2001; 49(4): 851 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.R Brehm, S.C Wolf, D Bertsch, M Klaussner, S Wesselborg, S Schuler, and K Schulze-Osthoff Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells Cardiovasc Res, February 1, 2001; 49(2): 430 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Riessen, M. Fenchel, H. Chen, D. I. Axel, K. R. Karsch, and J. Lawler Cartilage Oligomeric Matrix Protein (Thrombospondin-5) Is Expressed by Human Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 47 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Drachman, E. R. Edelman, P. Seifert, A. R. Groothuis, D. A. Bornstein, K. R. Kamath, M. Palasis, D. Yang, S. H. Nott, and C. Rogers Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2325 - 2332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K R KARSCH and A C NEWBY Stent magic! The genie has escaped from the bottle Heart, November 1, 2000; 84(5): 469 - 470. [Full Text]
|
|
|
|
 |
|
 J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hou, P. I. Rogers, P. M. Toleikis, W. Hunter, and K. L. March Intrapericardial Paclitaxel Delivery Inhibits Neointimal Proliferation and Promotes Arterial Enlargement After Porcine Coronary Overstretch Circulation, September 26, 2000; 102(13): 1575 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Herdeg, M. Oberhoff, A. Baumbach, A. Blattner, D. I. Axel, S. Schroder, H. Heinle, and K. R. Karsch Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1969 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Creel, M. A. Lovich, and E. R. Edelman Arterial Paclitaxel Distribution and Deposition Circ. Res., April 28, 2000; 86(8): 879 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chandrasekar and J.-F. Tanguay Platelets and restenosis J. Am. Coll. Cardiol., March 1, 2000; 35(3): 555 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Lehmann, J. J. Popma, J. A. Werner, A. J. Lansky, and R. L. Wilensky Vascular remodeling and the local delivery of cytochalasin B after coronary angioplasty in humans J. Am. Coll. Cardiol., March 1, 2000; 35(3): 583 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Liistro, G. Stankovic, C. Di Mario, T. Takagi, A. Chieffo, S. Moshiri, M. Montorfano, M. Carlino, C. Briguori, P. Pagnotta, et al. First Clinical Experience With a Paclitaxel Derivate-Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome Circulation, April 23, 2002; 105(16): 1883 - 1886. [Abstract] [Full Text] [PDF]
|
|